Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Chondrosarcoma 2Sinonasal undifferentiated carcinoma 1Immunoblastic Lymphadenopathy 1Glioma 1Esthesioneuroblastoma, Olfactory 1Cholangiocarcinoma 1

Interventions

Filgrastim 2Erlotinib Hydrochloride 2Docetaxel 2olaparib 1lutetium Lu 177 dotatate 1etoposide phosphate 1entinostat 1enasidenib 1Thalidomide 1SUB1 protein, human 1Ritonavir 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Irinotecan 1Indinavir 1Ifosfamide 1Gemcitabine 1Fluorodeoxyglucose F18 1Fentanyl 1FPP(RGD)2 1Etoposide 1Cyclophosphamide 1Cryosurgery 1Cisplatin 1Cetuximab 1Carboplatin 1Capecitabine 1Amifostine 17-hydroxystaurosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esthesioneuroblastoma, Olfactory × enasidenib × Sarcoma × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡